Literature DB >> 10993731

Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis.

K S Kim1, Z Y Sun, G Wagner, E L Reinherz.   

Abstract

The CD3 polypeptides (epsilon, gamma, and delta) are non-covalently associated signaling subunits of the T cell receptor which form non-disulfide linked epsilongamma and epsilondelta heterodimers. With the goal of investigating their structure, Escherichia coli expression was utilized to produce CD3 ectodomain fragments including the murine CD3epsilon subunit N-terminal Ig-like extracellular domain alone or as a single chain construct with that of CD3gamma. The latter links the CD3gamma segment to the C terminus of the CD3epsilon segment via a 26 amino acid peptide (scCD3epsilongamma26). Although CD3epsilon could be produced at high yield when directed to inclusion bodies, the refolded monomeric CD3epsilon was not native as judged by monoclonal antibody binding using surface plasmon resonance and was largely unstructured by (15)N-(1)H two-dimensional NMR analysis. In contrast, scCD3epsilongamma26 could be refolded readily into a native state as shown by CD, NMR and mAb reactivity. The linker length between CD3epsilon and CD3gamma is critical since scCD3epsilongamma16 containing a 16 residue connector failed to generate a stable heterodimer. Collectively, the results demonstrate that: (i) soluble heterodimeric fragments of CD3 can be produced; (ii) cotranslation of CD3 chains insures proper folding even in the absence of the conserved ectodomain stalk region (CxxCxE); and (iii) CD3epsilon has a more stable tertiary protein fold than CD3gamma. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993731     DOI: 10.1006/jmbi.2000.4098

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3.

Authors:  Lars Kjer-Nielsen; Michelle A Dunstone; Lyudmila Kostenko; Lauren K Ely; Travis Beddoe; Nicole A Mifsud; Anthony W Purcell; Andrew G Brooks; James McCluskey; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

2.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

Authors:  Damien Bresson; Lisa Togher; Evelyn Rodrigo; Yali Chen; Jeffrey A Bluestone; Kevan C Herold; Matthias von Herrath
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

3.  Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Steven M Lewis; Ricky L Lieu; Caroline Weldon; Carina Torres; Cody Fine; Micheal A Batt; Jonathan R Fitchett; Andrew L Glasebrook; Brian Kuhlman; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Solution structure of the CD3epsilondelta ectodomain and comparison with CD3epsilongamma as a basis for modeling T cell receptor topology and signaling.

Authors:  Zhen-Yu J Sun; Sun Taek Kim; Il Chul Kim; Amr Fahmy; Ellis L Reinherz; Gerhard Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-19       Impact factor: 11.205

5.  Expression and characterization of recombinant soluble porcine CD3 ectodomain molecules: mapping the epitope of an anti-porcine CD3 monoclonal antibody 898H2-6-15.

Authors:  Jaclyn Stromp Peraino; Christina E Hermanrud; Lauren Springett; Huiping Zhang; Guoying Li; Srimathi Srinivasan; Ashley Gusha; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  Cell Immunol       Date:  2012-05-18       Impact factor: 4.868

6.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.